Ημερολόγιο Συνεδρίων για το HIV/AIDS

December 2019
16th 02nd International Conference on Women and Child Health Colombo, Sri Lanka
February 2020
5th Viruses 2020 - Novel Concepts in Virology Barcelona, Spain
8th 2nd International Conference on Social Sciences, Humanities, Business Management & Economics Research (SHME) Paris, France
10th International Conference on HIV/AIDS 2020 Venice, Italy
13th LISD International World Research Congress on Health Sciences (IWRCHS) 2020, London London, United Kingdom
24th Healthcare Technologies and Public Health 2020 Lisbon, Portugal
26th International Conference on HIV/AIDS Prevention and Control Pretoria, South Africa
27th International Conference on Entrepreneurship, Business, Economics and Management Research MalΓ©, Maldives
27th ISBER International Conference on Teaching and Learning, Business Ethics, Management, Social Sciences & Humanities MalΓ©, Maldives
29th International Conference on African Studies Pretoria, South Africa
May 2020
16th International Conference on Infectious Diseases Colombo, Sri Lanka
18th 03rd International Conference on Pharmaceutical Sciences Colombo, Sri Lanka
21st World Congress on Control and Prevention of HIV/AIDS Osaka, Japan
24th 02nd International Conference on Community Medicine and Public Health Colombo, Sri Lanka
25th 03rd International Conference on Non Communicable Diseases Colombo, Sri Lanka
1


Lancet

Πρόσφατες δημοσιεύσεις στο περιοδικό The Lancet HIV

Tesamorelin, liver fat, and NAFLD in the setting of HIV

Management of abnormal liver function tests and cirrhosis, in the absence of hepatis B or C coinfection and high alcohol intake, has become an important issue in people with HIV on antiretroviral therapy (ART). One of the most common causes for abnormal liver function in both the general population and people living with HIV is non-alcoholic fatty liver disease (NAFLD), which has two forms: non-alcoholic steatohepatitis (NASH) or hepatic steatosis (figure). Between 6% and 35% of people globally1 have NASH-related cirrhosis, and it is the fastest growing indication for liver transplantation in the USA.

The global burden of HIV and prospects for control

HIV/AIDS continues to have devastating health effects globally, with over 39 million HIV/AIDS-related deaths to date and more than 36 million people living with HIV currently.1,2 Despite great advancements in antiretroviral therapy (ART) and worldwide progress towards implementation of treatment-as-prevention programmes, approximately 2 million people become newly infected with HIV every year.2,3 Retrospectively, evaluations of the HIV burden are integral to the assessment of control approaches.

Time to change cardiovascular prevention in people with HIV

Today, people with HIV live longer because of antiretroviral therapy (ART) but experience a higher risk of comorbidities, including atherosclerotic cardiovascular disease.1 Increased risk of cardiovascular disease might be due to not only classic risk factors, which are over-represented in the HIV-positive population, but also additional factors not present in the general population. These factors include chronic inflammation associated with HIV infection (even if successfully treated) and the use of some antiretroviral drugs, through mechanisms that are poorly understood.

About us

Στο hivaids.gr, φιλοξενούμε αφιλοκερδώς το "Πρόγραμμα Συνεργασίας" Μονάδων Λοιμώξεων για την ανάπτυξη διαδικτυακής τράπεζας κλινικών παραμέτρων. Το Πρόγραμμα δημιουργήθηκε από έναν γιατρό ειδικό στην HIV λοίμωξη με τη συμμετοχή των Μονάδων: Περισσότερα

% Αναπηρία και HIV

Νέος κανονισμός

Ενιαίος Πίνακας Προσδιορισμού Ποσοστού Αναπηρίας

Ημερολόγιο

@ Διαύγεια

ΔιαύγειαΔι@ύγεια

διαφάνεια στο κράτος

Διαδικτυακές αναρτήσεις διοικητικών αποφάσεων για το HIV/AIDS

Έρευνα

Σας έχει σπάσει ποτέ το προφυλακτικό κατά τη διάρκεια μιας ερωτικής επαφής;
Ναι
Όχι
Δεν χρησιμοποιώ

Επικοινωνία

Newsletter

Ανακοινώσεις

Χρήσιμες πληροφορίες